Tag Archives: Coronavirus

MGM Resorts to lay off 18,000 furloughed U.S. employees

(Reuters) – Casino operator MGM Resorts International informed its staff on Friday it would lay off 18,000 furloughed employees in the United States as the coronavirus-induced travel curbs hurt its operations.

The company will start the process on Monday, according to a letter from Chief Executive Officer Bill Hornbuckle to employees and seen by Reuters. MGM employed nearly 52,000 full time and 18,000 part-time people in the United States as of Dec. 31.

“Federal law requires companies to provide a date of separation for furloughed employees who are not recalled within six months. Regrettably, August 31, marks (that) date,” Hornbuckle said in the letter.

Many companies have decided to cut jobs as the U.S. economy recorded its sharpest contraction in at least 73 years in the second quarter due to pandemic-led disruptions, with corporate profits sinking deeper.

MGM was forced to close all of its casinos and furlough about 62,000 of its workforce in the United States in March due to the lockdowns.

It brought back tens of thousands of employees when many of its casinos opened for business as the restrictions eased, but it still had to leave out 18,000 of them.

Hornbuckle said that employees who will be laid off will remain in the company’s recall list and if hired back by the end of 2021, they shall retain their seniority and benefits.

Earlier in the day, Coca-Cola said it would cut thousands of jobs as sales had slumped, while United Airlines confirmed it was preparing for the biggest pilot furloughs and will need to remove 2,850 pilots this year.

(Reporting by Ankit Ajmera and Sanjana Shivdas in Bengaluru; Editing by Sherry Jacob-Phillips and Arun Koyyur)

Peru, with world’s deadliest outbreak, readies to start vaccine tests

By Marco Aquino

LIMA (Reuters) – Peru will start testing coronavirus vaccines from China’s Sinopharm and U.S. drugmaker Johnson & Johnson in September, researchers said, which should help the country gain faster access to inoculations once the vaccines are approved.

Sinopharm began this week to recruit up to 6,000 volunteers in Peru, which Reuters data indicates has the highest number of COVID-19 deaths in relation to its population size. A team of Chinese scientists is expected to arrive in the Andean nation next week to work with local researchers, said Germán Málaga, a doctor and lead vaccine investigator at Lima’s Cayetano Heredia University.

“This is going to happen around Sept. 3, to begin vaccinations on Sept. 8,” he said. Sinopharm’s clinical trials in Peru are being done with Cayetano Heredia and the state-run Universidad Mayor de San Marcos.

Peru has recorded around 622,000 cases of the coronavirus, the fifth highest case load in the world, and 28,277 deaths. It now has the world’s deadliest fatality rate per capita, with 86.67 deaths per 100,000 people, a Reuters tally shows, just ahead of Belgium.

Sinopharm will also do clinical coronavirus vaccine trials elsewhere in Latin America, including in Argentina.

Other Chinese laboratories that will be conducting trials in the region include Sinovac Biotech, which will work in Brazil and Chile, and Walvax Biotechnology Co Ltd and CanSino Biologics Inc, which will test in Mexico, authorities have said.

Johnson & Johnson’s Janssen unit will start tests with some 4,000 volunteers in Peru around Sept. 24, Prime Minister Walter Martos told reporters on Thursday.

“We are contacting other companies, laboratories, from Britain and other countries that are going to help us immunize at least 70% of the local population,” Martos said.

J&J said earlier this week that it would conduct Phase III trials for its vaccine in Chile, Argentina and Peru.

Peru, a country of nearly 33 million people and the world’s no. 2 copper producer, has been particularly hard-hit by the pandemic, both in terms of infections and economic impact. The economy crumbled over 30% in the second quarter of the year.

The death toll could also be higher than official figures suggest. A national registry shows that between April and August there were 68,192 more deaths compared to the same period in 2019. Excess deaths often give a better indication of the true number of fatalities.

Researcher Málaga and Carlos Castillo, the chief adviser for immunizations and vaccines at Peru’s health ministry, said that carrying out clinical trials would help Peru get faster access to vaccines when they were ready.

“There is an unwritten agreement, in the sense that in the country where a clinical trial is being carried out, it has priority access to vaccine availability,” Castillo said.

(Reporting by Marco Aquino and Reuters TV; Editing by Adam Jourdan and Rosalba O’Brien)

J&J to start mid-stage coronavirus vaccine trials in three European countries

By Nathan Allen

MADRID (Reuters) – Johnson & Johnson’s Janssen unit will begin mid-stage trials for its coronavirus vaccine in Spain, the Netherlands and Germany next week, Spain’s health minister said on Friday, as the U.S. drugmaker expands testing for its experimental shot.

The Phase II trial will last two months and include 550 participants across the three countries, including 190 people in Spain, Salvador Illa told a news conference in Madrid.

“It’s a vote of confidence in our health system,” Illa said, adding it was the first human trial for a coronavirus vaccine to be approved in Spain.

The study will focus on healthy people between the ages of 18 and 55 as well as people over 65.

Johnson & Johnson said the study will evaluate the safety and the ability to induce an immune response from single dose and two-dose regimens of the vaccine candidate, the company said in a statement.

Spain, which has western Europe’s highest tally of coronavirus cases, is also working with AstraZeneca via the European Union’s vaccine procurement program to secure sufficient doses.

J&J’s website says if the latest trials are successful, it will begin final Phase III studies, in which even more volunteers will receive the experimental vaccine.

More than 150 potential vaccines are being developed and tested globally to combat the COVID-19 pandemic, with 30 in human trials.

There is so far no approved vaccine, except one authorized in Russia before large-scale trials.

J&J is carrying out tests in the United States and Belgium, and this week added Chile, Argentina and Peru to the list of Latin American nations where it plans to conduct Phase III trials on 60,000 volunteers, in a study that will also cover Brazil, Colombia and Mexico.

The company’s potential vaccine uses “viral vectors” to generate immune responses, similar to the approach taken by the University of Oxford and AstraZeneca in their experimental vaccine, as well as China’s CanSino.

(Reporting by Nathan Allen and Jose Elías Rodríguez; editing by Mark Potter and Jason Neely)

Sinovac’s coronavirus vaccine candidate approved for emergency use in China- source

BEIJING (Reuters) – Sinovac Biotech Ltd’s coronavirus vaccine candidate CoronaVac was approved in July for emergency use as part of a program in China to vaccinate high-risk groups such as medical staff, a person familiar with the matter said.

China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm), also said it had obtained emergency use approval for a coronavirus vaccine candidate in social media platform WeChat on Sunday.

CNBG, which has two vaccine candidates in phase 3 clinical trials, did not say which of its vaccines had been cleared for emergency use.

China has been giving experimental coronavirus vaccines to high-risk groups since July, and a health official told state media in an interview aired last week that authorities could consider modestly expanding the emergency use program to try to prevent possible outbreaks during the autumn and winter.

Officially, China has given little details on which vaccine candidates have been given to high-risk people under the emergency use program and how many people have been vaccinated.

State media reported in June, prior to the emergency use program, that employees at state firms travelling overseas were allowed to take one of the two vaccines being developed by CNBG, while China’s military had also approved the use of CanSino Biologics’ vaccine candidate.

Seven vaccines against the coronavirus are in final trial stages around the world, and four of them are from China.

But no vaccine has yet passed the final stage of trials proving it is safe and effective – conditions usually required to be met to get regulatory approval for mass use. COVID-19 has killed over 800,000 people worldwide.

(Reporting by Roxanne Liu in Beijing and Miyoung Kim in Singapore; Editing by Ana Nicolaci da Costa)

Prayers and faxed letters: Texas woman buries husband who died of COVID-19

By Callaghan O’Hare and Maria Caspani

HOUSTON (Reuters) – As hundreds of thousands of people in Texas fled their homes ahead of Hurricane Laura on Wednesday, Michelle Gutierrez was in Houston burying her husband David, who died of COVID-19 on Aug. 14.

The couple would have celebrated their 10th wedding anniversary on Sept. 4, a few days after David’s 54th birthday. Michelle and David met at a mechanic’s shop in Houston in 2009, when he had stepped in as a translator to help her with a mechanic who only spoke Spanish.

He then offered to fix her computer, and the rest is history. They built a life together in Houston, where they raised five children and he worked as a software engineer.

In early July, David was hospitalized after his symptoms of COVID-19, the disease caused by the new coronavirus, worsened. His wife and two daughters had tested positive but showed no symptoms.

David would fight the virus for over a month at Houston’s St. Luke’s in The Woodlands hospital, where he eventually died of heart failure.

“It’s been a roller coaster, every day is different,” Michelle said on the day of his funeral, her voice breaking with emotion. “One day you’re fine and the next day, you walk around and memories flood your mind… You just wish this was all a dream.”

About a week after her husband was hospitalized, Michelle and her daughters gathered under his hospital window to pray for him.

“And then after that first night I was like, ‘You know what, I’m gonna come in every night, honey, I’m going to be here every night, praying for you and just being there in spirit’,” she said.

And so she did, until the Friday in August when David passed away.

Michelle said she kept trying to communicate with her husband as his condition worsened. At first, before he was put on a ventilator, they managed to text one another, she said. But once he was in a coma, she began faxing letters to the hospital, and nurses would read them aloud to him.

David is one of thousands who have succumbed to the coronavirus in Texas, where a spike in cases in June and July strained hospital systems as the virus engulfed many southern states.

Nearly 180,000 people in the United States have died from COVID-19, the highest in the world, with 5.8 million cases recorded nationwide, according to a Reuters tally, also the highest in the world.

At David’s wake, a bottle of hand sanitizer and social distancing signs were prominently displayed as masked mourners walked to the casket to bid their farewells.

As for the future, Michelle said she was enrolling in a college nursing program. She had already planned to do so before her husband’s passing, but feels more motivated now.

“That’s more so now than before after seeing how these nurses took care of David and they were wonderful… And I could not have done it without them.”

(Reporting by Callaghan O’Hare in Houston, Texas and Maria Caspani in New York; Writing by Maria Caspani; Editing by Bernadette Baum)

U.S. COVID-19 deaths exceed 180,000, cases continue to fall

By Lisa Shumaker

(Reuters) – U.S. deaths from the novel coronavirus topped 180,000 on Thursday after a surge of new cases in June and July, many of them in hotspots like California, Florida, and Texas.

There were some signs of an improving outlook. Last week, deaths fell 17% from the prior week and below an average of 1,000 a day for the first time in weeks, according to a Reuters analysis.

However, while U.S. metrics on cases, deaths, hospitalizations and test positivity rates were declining, health experts warned there could be another surge as schools reopen and colder weather forces more gatherings indoors.

This week, the U.S. Centers for Disease Control and Prevention (CDC) said people exposed to COVID-19 but not symptomatic may not need to be tested. This contradicted earlier guidance from the CDC, shocking doctors and politicians and prompting accusations that it may have been based not on sound science but on political pressure from the Trump administration.

The governors of New York, New Jersey and Connecticut slammed the CDC’s move as “reckless” and “not based on science,” and said they will not change testing guidelines in their states.

“CDC and HHS have not shared their scientific rationale for this change in policy, which substitutes sound science-based public health guidance with the president’s misinformation,” they said in a joint statement. “Health experts recommend testing close contacts of individuals with COVID-19 to identify and prevent asymptomatic spread. This type of robust testing by our states has been a key factor in our success so far to flatten the curve in the tri-state area.”

On Wednesday, the top U.S. government infectious disease expert Anthony Fauci told CNN he was having surgery during discussion of the change and expressed worry about the CDC’s move.

U.S. confirmed cases are now over 5.8 million – the highest total in the world. The U.S. death toll is also the world’s highest.

On a per capita basis, the United States ranks 12th in the world for the number of deaths, with 54 deaths per 100,000 people, and tenth in the world for cases, with 1,774 cases per 100,000 residents, according to a Reuters analysis.

U.S. consumer confidence dropped in August to its lowest in more than six years, as households worried about the labor market and incomes, casting doubts on the sustainability of the economy’s recovery from the COVID-19 recession.

The ebb in confidence followed the expiration of a $600 weekly unemployment benefit supplement on July 31.

For weeks, Republicans and Democrats have been deadlocked over the size and shape of a fifth coronavirus-response bill, on top of the approximately $3 trillion already enacted into law.

(Reporting by Lisa Shumaker, additional reporting by Maria Caspani, Editing by Rosalba O’Brien and David Gregorio)

FDA warns against hand sanitizers that look like drinks

(Reuters) – The U.S. Food and Drug Administration (FDA) on Thursday warned of alcohol-based sanitizers being packaged and sold in containers that appear like food or drinks.

At a time when health agencies are pushing for better hand hygiene to curb the spread of the coronavirus in the United States, the top health regulator found many hand sanitizers look like beer cans, children’s food pouches, water bottles, juice bottles and vodka bottles.

Some of them were being sold with cartoons for children and had added food flavors such as chocolate or raspberry.

“These products could confuse consumers into accidentally ingesting a potentially deadly product,” FDA Commissioner Stephen Hahn said in a statement.

He warned against adding scents with food flavors to hand sanitizers as it would lead to children mistaking it for food and result in alcohol poisoning.

The Centers for Disease Control and Prevention (CDC), which has backed use of sanitizers if soap and water are not available, has reported several cases of methanol poisoning, some even fatal, caused by swallowing alcohol-based hand sanitizers.

(Reporting by Vishwadha Chander in Bengaluru; Editing by Arun Koyyur)

U.S. CDC reports 177,759 deaths from coronavirus

(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) on Wednesday said the number of deaths due to the coronavirus had risen by 1,142 to 177,759 and also reported 5,752,653 cases, an increase of 37,086 cases from its previous count.

The CDC reported its tally of cases of the respiratory illness known as COVID-19, caused by a new coronavirus, as of 4 pm ET on Aug. 25 versus its previous report a day earlier.

The CDC figures do not necessarily reflect cases reported by individual states.

(Reporting by Dania Nadeem in Bengaluru, Editing by Sherry Jacob-Phillips)

Gaza man dies of coronavirus as lockdown imposed to curb first outbreak

By Nidal al-Mughrabi

GAZA (Reuters) – Gaza reported one coronavirus death and at least 10 new cases of infection on Wednesday as the blockaded Palestinian enclave sought to control its first public outbreak of the disease.

Hamas-controlled security forces enforced a lockdown in all cities in the coastal territory, warning people to stay at home or to wear face masks if they had to go out for emergencies.

Health officials said the 61-year-old man who died had pre-existing conditions and had been on a respirator.

Ten more cases were reported on Wednesday, six of them in Maghazi refugee camp where the first four infections were discovered on Monday, and another four in Gaza City and the northern area of the enclave of 2 million people.

The new infections added to concerns among local and international health organizations about Gaza’s potentially disastrous combination of poverty, densely populated refugee camps and limited hospital capacity.

Until Monday the 360 square-kilometre (139 square-mile) coastal strip had reported no infections outside border quarantine facilities for new arrivals.

Facing for the first time a situation that the rest of the world has been dealing with for months, Gazans have been going online to share experiences and voice their concerns.

“We are now alone with Corona, with the blazing sun and the power supply being cut off. Corona came to empty pockets and homes on the brink of sadness and anger,” wrote one Gaza resident on Twitter.

The 40 kilometre-long territory is sealed off from the outside world by Israeli walls, watchtowers and gunboats along 90% of its border and coastline, and by Egypt along a narrow strip to the south.

Both countries impose tight restrictions on movement in and out of Gaza, citing security concerns over Hamas, which is regarded as a terrorist organization by Israel and the United States.

The blockade is thought to be one reason why Gaza remained relatively virus-free, with many of its residents comparing their situation to a permanent lockdown.

The United Nations agency dealing with Palestinian refugees, UNRWA, said it was considering alternative plans to continue under lockdown the health, education and food services it provides to more than half Gaza’s population.

UNRWA spokesman Adnan Abu Hasna said clinics remained open but staffers were providing medical consultations over the phone, and some medication was being delivered to homes.

(Additional reporting by Zainah El-Haroun in Ramallah; Writing by Stephen Farrell and Dan Williams; Editing by William Maclean and Hugh Lawson)

Moderna’s COVID-19 vaccine shows similar immune response in old and young

(Reuters) – Moderna Inc said on Wednesday that an analysis of the early-stage data of its experimental COVID-19 vaccine showed it induced immune responses in older adults that were similar to younger participants.

The drug developer is one of the leading U.S. contenders in the race to develop a safe and effective vaccine against the novel coronavirus and its candidate, mRNA-1273, is already in the Phase 3 stage of human testing.

Moderna is now reporting interim data from the Phase 1 study, which includes new analysis from 20 additional people and details on how the vaccine performs in older people.

The analysis looked at 100 micro gram dosage that has been selected for the larger Phase 3 trial. Moderna said the immune responses in those aged between 56 and 70 years, above 70 and those in the age-group of 18 and 55 were similar.

The data is being presented at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices meeting on Wednesday.

The company has so far enrolled over 13,000 participants in the late-stage study and about 18% of the total participants are Black, Latino, American Indian or Alaska Native, groups that are the hardest hit by the pandemic.

Moderna, which has no drugs in the market, has received nearly $1 billion from the U.S. government under a plan to speed up vaccine development for COVID-19. It has also struck a $1.5 billion supply agreement with the United States.

Shares of the drug developer rose more than 7% to $71.35 after the data. They have more than tripled in value so far this year and results from its studies have boosted the broader market.

(Reporting by Manojna Maddipatla in Bengaluru; Additional reporting by Ankur Banerjee; Editing by Arun Koyyur)